ArticleMedicine2021

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.

Li Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.